- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06380686
Plataforma de investigación clínica del carcinoma de cabeza y cuello para biomarcadores, tratamiento y resultados moleculares y sanguíneos (HEAT)
Plataforma de investigación clínica del carcinoma de cabeza y cuello para estudios moleculares y sanguíneos
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The advent of checkpoint inhibitors has changed the treatment landscape in SCCHN and new treatment sequences have entered clinical practice.
More in-depth knowledge of tumor biomarkers are important measures for optimization of treatment strategies in SCCHN. In addition to this, investigations may involve other assessments, which will be explored separately, such as molecular testing. These tests are then linked to the core data set and will allow to associate such measures with outcomes. This concept is flexible and allows for rapid integration of contemporary research questions in a timely manner.
Furthermore, insights into the treatment reality for recurrent/metastatic salivary gland carcinoma and other rare tumor entities (SNUC, etc.) are urgently needed, as there is currently no established standard of care.
The monoclonal antibody cetuximab in combination with platinum and fluorouracil (EXTREME) has been the standard of care for recurrent or metastatic (r/m) SCCHN for over a decade.1 Recently, the immune checkpoint inhibitors (CPIs) nivolumab and pembrolizumab have changed the therapeutic landscape of patients with r/m SCCHN. Nivolumab is considered as therapeutic standard after failure of platinum-based therapy based on the results of the phase III Checkmate-141 trial.2 In addition, pembrolizumab has become the new standard in the first-line setting in combination with platinum/fluorouracil chemotherapy or as monotherapy for patients with programmed cell death ligand 1 (PD-L1) positive tumors based on the data from the phase III Keynote-048 trial.3 Moreover, cetuximab in combination with platinum and docetaxel (TPEx) has emerged as a less toxic alternative to the EXTREME regimen.4 Due to the shifting first-line treatment landscape, data to guide contemporary 2nd line therapy are scarce and the optimal treatment sequence remains vague.2,5,6 The implementation of biomarkers and selection of patients in a real-world setting are areas of academic interest. In addition, the assessment of treatment outcomes in rare entities are underrepresented in pivotal trials, and as a matter of fact, may be completely excluded. However, broad labels permit the use of novel agents, but a larger body of evidence is needed to substantiate such treatment choices. HEAT seeks to address these questions by inclusion of a real-world patient population and continuous assessment of oncological outcomes by means of a core clinical data set implemented into HEAT.
Overall, HEAT is a study platform, which continuously assesses clinical outcomes and modularly integrates additional measures to enable rapid answers to research questions.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Project Manager
- Número de teléfono: +49 (0)30 814534431
- Correo electrónico: kht-register@aio-studien-ggmbh.de
Ubicaciones de estudio
-
-
-
Essen, Alemania, 45147
- Aún no reclutando
- Universitätsklinikum Essen
-
Contacto:
- Michael Pogorzelski, Dr. med.
- Número de teléfono: +49 (0) 157 38 79 55 41
- Correo electrónico: Michael.Pogorzelski@uk-essen.de
-
Hanover, Alemania, 30161
- Reclutamiento
- Onkologie/Studienzentrum am Raschplatz GbR
-
Contacto:
- Eyck von der Heyde, Dr. med.
- Número de teléfono: +49 (0) 511 86649985
- Correo electrónico: vdheyde@onkologie-am-raschplatz.de
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adult patients with histologically or cytologically confirmed malignancy of the head neck area including but not limited to
- squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx or larynx
- not amenable for curative treatment who receive palliative systemic treatment or best supportive care.
Descripción
Inclusion Criteria:
- Age ≥ 18 years
- Able to understand and willing to sign written informed consent
- Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
- Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
- Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
Exclusion Criteria: none
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sociodemographic factors
Periodo de tiempo: 3 years
|
Highest level of education, Employment status, Current professional activity, Professional risk factors, Level of self-sufficiency, Care degree |
3 years
|
|
Treatments
Periodo de tiempo: 3 years
|
Types of local therapies (surgery, radiotherapy, radiochemotherapy), systemic therapy and therapeutic sequences |
3 years
|
|
Response rates
Periodo de tiempo: 3 years
|
Response rates |
3 years
|
|
Treatment decision
Periodo de tiempo: 3 years
|
Physician-reported parameters affecting treatment decision |
3 years
|
|
Progression-free survival
Periodo de tiempo: 3 years
|
Progression-free survival |
3 years
|
|
Time-to-treatment-failure
Periodo de tiempo: 3 years
|
Time-to-treatment-failure |
3 years
|
|
Overall survival
Periodo de tiempo: 3 years
|
Overall survival |
3 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Victor Grünwald, Prof. Dr., Universitätsklinikum Essen
- Investigador principal: Michael Pogorzelski, Dr., Universitätsklinikum Essen
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias de Cabeza y Cuello
- Neoplasias Glandulares y Epiteliales
- Carcinoma
- Carcinoma De Células Escamosas
- Carcinoma de células escamosas de cabeza y cuello
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Métodos epidemiológicos
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Salud pública
- Medio ambiente y salud pública
- Recopilación de datos
Otros números de identificación del estudio
- AIO-KHT-0322/ass
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .